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Uterine fibroids affect up to 77% of women by menopause and account for up to $34
billion in healthcare costs each year. Although fibroid risk is heritable, genetic risk for
fibroids is not well understood. We conducted a two-stage case-control meta-analysis
of genetic variants in European and African ancestry women with and without fibroids
classified by a previously published algorithm requiring pelvic imaging or confirmed
diagnosis. Women from seven electronic Medical Records and Genomics (eMERGE)
network sites (3,704 imaging-confirmed cases and 5,591 imaging-confirmed controls)
and women of African and European ancestry from UK Biobank (UKB, 5,772 cases
and 61,457 controls) were included in the discovery genome-wide association study
(GWAS) meta-analysis. Variants showing evidence of association in Stage I GWAS
(P < 1 × 10−5) were targeted in an independent replication sample of African and
European ancestry individuals from the UKB (Stage II) (12,358 cases and 138,477
controls). Logistic regression models were fit with genetic markers imputed to a
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1000 Genomes reference and adjusted for principal components for each race-
and site-specific dataset, followed by fixed-effects meta-analysis. Final analysis with
21,804 cases and 205,525 controls identified 326 genome-wide significant variants
in 11 loci, with three novel loci at chromosome 1q24 (sentinel-SNP rs14361789;
P = 4.7 × 10−8), chromosome 16q12.1 (sentinel-SNP rs4785384; P = 1.5 × 10−9)
and chromosome 20q13.1 (sentinel-SNP rs6094982; P = 2.6 × 10−8). Our statistically
significant findings further support previously reported loci including SNPs near WT1,
TNRC6B, SYNE1, BET1L, and CDC42/WNT4. We report evidence of ancestry-specific
findings for sentinel-SNP rs10917151 in the CDC42/WNT4 locus (P = 1.76 × 10−24).
Ancestry-specific effect-estimates for rs10917151 were in opposite directions (P-Het-
between-groups = 0.04) for predominantly African (OR = 0.84) and predominantly
European women (OR = 1.16). Genetically-predicted gene expression of several
genes including LUZP1 in vagina (P = 4.6 × 10−8), OBFC1 in esophageal mucosa
(P = 8.7 × 10−8), NUDT13 in multiple tissues including subcutaneous adipose tissue
(P = 3.3 × 10−6), and HEATR3 in skeletal muscle tissue (P = 5.8 × 10−6) were
associated with fibroids. The finding for HEATR3 was supported by SNP-based
summary Mendelian randomization analysis. Our study suggests that fibroid risk variants
act through regulatory mechanisms affecting gene expression and are comprised of
alleles that are both ancestry-specific and shared across continental ancestries.
Keywords: uterine fibroids, genome-wide association study (GWAS), trans-ethnic, meta-analysis electronic
health record (EHR), genetically predicted gene expression (GPGE), genetic architecture
INTRODUCTION
Uterine leiomyomata, also known as fibroids, are the most
common female pelvic tumor and are the indication for at
least 37% of all hysterectomies, or approximately 200,000
hysterectomies annually in the United States (Cramer and Patel,
1990; Wu et al., 2007). The estimated financial burden in the
United States ranges from $9.4 billion per year in direct costs, to
$34.4 billion per year considering all costs(Cardozo et al., 2012).
Fibroid prevalence estimates range from 20 to 80%, increasing
with age up to menopause (Cramer and Patel, 1990; Marshall,
1997; Vollenhoven, 1998).
Known risk factors for fibroids include African ancestry,
African American (AA) race (Ojeda, 1979; Cramer and Patel,
1990; Marshall, 1997; Faerstein et al., 2001a,b; Baird et al.,
2003), early age-at-menarche (Lumbiganon et al., 1996; Samadi
et al., 1996; Marshall et al., 1998; Faerstein et al., 2001a;
Wise et al., 2004; Dragomir et al., 2010), high body mass
index (BMI) (Moore et al., 2008; Takeda et al., 2008; Stewart
et al., 2017), and increasing age up to menopause (Baird
et al., 2003). Higher parity is inversely associated with fibroids,
likely due to pregnancy-related hormonal and physical changes
including postpartum uterine involution (Baird and Dunson,
2003; Laughlin et al., 2010, 2011).
Multiple lines of evidence suggest fibroids are influenced by
genetic risk factors. Twin and familial aggregation studies in
several European populations estimate heritability of fibroids
between 26 and 69% (Kurbanova et al., 1989; Snieder et al.,
1998; Luoto et al., 2000). Additionally, the observations that AA
women develop fibroids at an earlier age, have more numerous
and larger fibroids, and have a higher lifetime incidence of
fibroids further suggest a genetic contribution to fibroid risk
(Baird et al., 2003). Various growth factors (Sozen and Arici,
2002), reproductive factors (Parazzini et al., 1996), dysregulation
of microRNAs (Marsh et al., 2008), shortening of telomeres
(Bonatz et al., 1998), excessive production of disorganized
extracellular matrix (Sozen and Arici, 2002; Malik et al., 2010),
and acquired chromosomal aberrations have also been noted
as potential factors contributing to the development of fibroids
(El-Gharib and Elsobky, 2010).
Cha et al. (2011a) used a two-stage case-control genome-
wide association study (GWAS) to examine risk for
fibroids in a population of Japanese women from hospitals
affiliated with the BioBank Japan Project. They reported
genome-wide significant single nucleotide polymorphisms
(SNPs) in three chromosomal regions, 10q24.33, 11p15.5,
and 22q13.1, corresponding to nearby genes OBFC1,
BET1L, and TNRC6B, respectively. The associations at
BET1L and TNRC6B were previously replicated in our
imaging-confirmed case-control study of white women
from the Vanderbilt University biorepository (BioVU)
(Edwards et al., 2013b).
Eggert et al. (2012) performed a large-scale genome-wide
linkage scan (GWLS) reporting discoveries in chromosomes
10p11 and 3p21. They reported a genome-wide significant result
for rs4247357, an intronic SNP in CCDC57, from self-reported
case-control investigations from the Women’s Genome Health
Study and the Australian Cohort Association Study. However, the
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regions identified in the Japanese GWAS (Cha et al., 2011a), the
Australian GWLS and the European ancestry GWAS do not have
any notable overlaps.
We have also previously published a GWAS of fibroid risk
in recent African ancestry populations, as well as an admixture
mapping study of fibroid risk considering interactions with BMI
(Giri et al., 2017; Hellwege et al., 2017a). In those studies the
CYTH4 (chromosome 22q13.1) locus was detected in African
ancestry populations (Hellwege et al., 2017a), as well as the
ADTRP (chromosome 6p24) and TFPI (chromosome 2q 31-32)
loci for ancestry-BMI interactions (Giri et al., 2017).
Two recent GWASs have combined data from white British
participants from the United Kingdom Biobank (UKB) with
Icelandic (Rafnar et al., 2018) and Finnish (Välimäki et al.,
2018) fibroid cases and controls. These studies reported variants
in 16 and 22 loci, respectively, to be associated with uterine
fibroids (Rafnar et al., 2018; Välimäki et al., 2018). Both studies
replicated the previously reported loci from the Japanese study,
OBFC1, BET1L, and TNCR6B, as well as both identifying several
novel loci, including TP53, TERT, ATM, CDC42/WNT4, and
SYNE1/ESR1. These studies also used males as controls, which
may bias to the null hypothesis when male controls carry risk-
increasing alleles but they do not have a uterus in which to grow
fibroids, or may induce spurious associations.
Despite the high prevalence of fibroids and strong racial
disparities between European Americans (EA)s and AAs, no
trans-ethnic GWAS meta-analysis combining AA and EA women
has been conducted. We performed a two-stage trans-ethnic
GWAS of uterine fibroid risk in women of predominantly African
and European ancestries in the electronic Medical Records
and Genomics (eMERGE) network and the UKB (McCarty
et al., 2011; Gottesman et al., 2013) to identify both shared




Stage I GWAS analyses included fibroid cases and female
controls from eleven European and African ancestry-specific
subsets, nine identified from sites in the eMERGE network
and two identified from African and European subsets of
the UKB from the 150K release. eMERGE sites included
the BioVU Biobank at Vanderbilt University (BioVU), the
Mayo Clinic, Mount Sinai, Marshfield Clinic, Northwestern
University, and Group Health (Table 1 and Figure 1). A detailed
description of the structure and organization of the eMERGE
network has been previously published (McCarty et al., 2011).
Clinical data from eMERGE cohorts rely on multiple sources
including diagnostic and procedure codes, basic demographics,
discharge summaries, progress notes, health history, multi-
disciplinary assessments, laboratory values, imaging reports,
medication orders, and pathology reports. The Institutional
Review Boards at all participating institutions in the eMERGE
network approved this study. Genotype data utilized in this
study from BioVU and the eMERGE network are publically
available in NCBI dbGaP, accession numbers phs001409.v1.p1
TABLE 1 | Race- and site-specific characteristics of women across participating eMERGE sites by fibroid case-control status.









BioVU AA 578 804 40 (11) 41 (15) 0.150 31 (14) 26 (16) <0.0001
BioVU EA 1,195 1,164 46 (12) 56 (19) <0.0001 27 (11) 25 (12) <0.0001
BioVU-II EA 439 405 47 (12) 49 (16) 0.04 28 (10) 25 (13) 0.0002
Mount Sinai:
BioMeTM
AA 317 331 48 (10) 45 (16) 0.004 32 (9) 32 (10) 0.999
Mount Sinai AA 74 78 59 (10) 63 (12) 0.027 NA NA NA
eMERGE I
(Northwestern)




EA 580 1,429 53 (11) 68 (12) <0.0001 29 (6) 28 (6) 0.0007
Northwestern EA 224 244 50 (10) 37 (8) <0.0001 26 (7) 26 (6) 0.999
Mayo Clinic EA 213 1,084 55 (11) 65 (11) <0.0001 31 (18) 29 (9) 0.115
UKB African 225 649 50 (6) 54 (7) 0.002 30 (6) 30 (6) 0.229
UKB European 5,517 60,808 56 (8) 58 (7) <0.0001 28 (5) 27 (5) <0.0001
Stage I Total 9,446 67,048
UKB – Replication African 247 713 49 (7) 54 (7) <0.001 31 (6) 31 (6) 0.999
UKB – Replication European 12,111 137,764 57 (8) 58 (7) <0.001 28 (5) 27 (5) <0.0001
Stage II Total 12,358 138,477
Total 21,804 205,525
AA, African American; BioVU, Bio-repository at Vanderbilt University; BMI, body mass index; EA, European American; eMERGE, electronic Medical Records and Genomics;
eMERGE I (Marshfield/NU/Group Health), Participants from these sites were genotyped with the same chip, harmonized together and analyzed as one set; SD, standard
deviation; NA, Not Available; NU, Northwestern University; UKB, UK Biobank.
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FIGURE 1 | Flow-chart showing study stages and types of analyses.
and phs000360.v2.p1, respectively. Data from UK Biobank
may be obtained by qualified investigators upon application
with UK Biobank.
The UKB is a large long-term biobank study in the
United Kingdom started in 2006, capable of investigating the
role of multiple environmental and genetic factors associated
with disease development. The study enrolled 499,589 adults 40–
69 years of age in 2006 and the planned follow-up is for 30 years
since enrollment.
There were two releases of the UKB genetic dataset; the
first release included 150K individuals and the second release
included the entire 500K individuals in the study. Stage I of this
study utilized European and African-ancestry samples in the first
release, and Stage II included European and African-ancestry
samples from the second release, excluding individuals from the
first release to provide independent replication sets.
Fibroid Diagnosis for eMERGE Cohorts
A detailed description and validation of our fibroid phenotyping
algorithm has been published (Feingold-Link et al., 2014). Briefly,
the algorithm uses a combination of demographic inclusion
and exclusion criteria, International Classification of Diseases
9th edition (ICD-9) diagnostic codes, Current Procedural
Terminology (CPT) codes, and keyword exclusions from specific
notes and reports of a participant in order to categorize cases
and controls. Keyword searches of EMRs were conducted using
natural language processing (NLP) algorithms available for those
allowing EMR data for research. For individuals who lacked
a diagnostic code for fibroids, but potentially had a history
of fibroids documented, the NLP approach reliably identified
these participants.
Eligible participants were women at least 18 years of age and
required to have mention of at least one imaging procedure
performed in which a fibroid would be identified were it
present. Participants with procedure codes (one or more for
cases and two or more on separate dates for controls) for
imaging with ultrasound, magnetic resonance imaging (MRI),
or computed tomography (CT) were included. Then, cases
required evidence of a fibroid diagnosis defined by either an
ICD-9 code indicating the presence of fibroids or ICD and
CPT codes indicating a history of fibroid treatment procedures
(e.g., myomectomy, uterine artery embolization, hysterectomy).
Controls were participants who had two or more imaging events
on separate dates without fibroids noted and did not have a
fibroid diagnosis or history of fibroid treatment procedures.
Women without an intact uterus (e.g., having had a prior
hysterectomy) based on CPT procedural codes and text mentions
of hysterectomy were considered ineligible to be controls.
Controls were density matched to cases for imaging technology
and timing of imaging technology within 3–5 years of case
pelvic imaging to ensure comparable distribution of imaging
technology across cases and controls. Finally, to reduce the
potential for misclassification of would-be cases as controls, the
oldest available controls were chosen within similar bins of pelvic
imaging technology windows as for cases. The same algorithm
was applied uniformly across all contributing eMERGE sites
(Feingold-Link et al., 2014).
Fibroid Diagnosis for UKB
Women 18 years of age or older with diagnosis of uterine
leiomyomata as defined by the presence of non-cancer illness
codes f.20002.0.0-28, f.20002.1.0-28, f.20002.2.0-28, or ICD10
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codes f.41201.0.0-31, f.41202.0.0-379, f.41203.0.0-27, f.41204.0.0-
27, and f.41205.0.0-27 were defined as fibroid cases in the
UKB. All other women, over the age of 45 and for who
medical codes for myomectomy, hysterectomy or uterine
artery ablation were not present were considered controls.
Information regarding age, and BMI at enrollment and race
were abstracted.
Genotyping and Quality Control
eMERGE Studies
Identical quality control (QC) was conducted within each cohort.
QC summaries for each individual cohort are provided in
Supplementary Table 1. QC involved excluding individuals with
low genotyping efficiency (<98%), related individuals (keeping
one individual from a related pair), and subjects with inconsistent
reported versus genetically determined sex (Verma et al., 2014).
All SNPs were tested for deviation from Hardy-Weinberg
equilibrium (HWE), stratified by race (Purcell et al., 2007). We
excluded SNPs with HWE P ≤ 10−6, low genotyping efficiency
(<98%), minor allele frequency (MAF) < 1%, and SNPs that did
not map to a chromosomal position. Furthermore, we aligned
SNPs to strand by comparing allele frequencies of SNPs in each
race and genotyping platform-specific GWAS set to respective
allele frequencies from SNPs in the 1000 Genomes build 37
reference populations. Plots of allele frequencies were created to
identify and exclude SNPs within each dataset with discordant
allele frequencies (absolute value difference > 0.1) compared with
their respective reference populations. Palindromic SNPs (AT
and GC pairs) with MAF > 40% for which the reference strand
could not be determined with certainty were also excluded.
UKB Analysis Sets
UKB genetic data followed standard quality control procedures.
Detailed information regarding quality control and imputation
can be found through the UKB documentation1. Briefly, UKB
samples were genotyped with the Affymetrix UK Biobank Axiom
array and imputed with the Haplotype Reference Consortium
(HRC) and the UK10K haplotype reference resources to yield
96 million imputed variants in 487,409 individuals (version 3;
Project # 13869; accessed on Jul 31, 2018). We used these
genotyped and imputed variants in women of European and
African ancestry for analysis.
We used EIGENSTRAT to calculate the top 10 principal
components (PCs) (Price et al., 2006). Up to five top PCs were
used as covariates in regression models to control for potential
confounding by population stratification.
Statistical Analyses
IMPUTE version 2.2.2 software was used to impute ungenotyped
SNPs in samples and genotypes that passed QC for the eMERGE
network studies (Howie et al., 2009). GWAS data were phased
using SHAPEIT software prior to imputation (Delaneau et al.,
2011). The most up-to-date data from the 1000 Genomes
reference panel was used as reference data to impute un-
genotyped SNPs using the entire cosmopolitan panel rather
1www.ukbiobank.ac.uk
than only using race/ethnicity-specific reference populations
(build 37, 2013) (Howie et al., 2009). Studies have shown that
using the entire reference panel increases imputation accuracy
(Howie et al., 2011).
Relevant participant characteristics between fibroid cases and
controls were compared with Student’s t-test with the assumption
of unequal variance for continuous traits (Table 1). Stata, version
11 (StataCorp, College Station, TX, United States) was used
to compare means.
We followed a two-stage genome-wide meta-analysis
approach to evaluate the association between genetic markers
and fibroids. Studies in Stage I were evaluated for eligible and
available genotyped/imputed variants throughout the genome.
Summary statistics from individual studies were meta-analyzed
using inverse-variance weighted fixed effects meta-analysis
approach. Selected variants (N = 860 SNPs) from Stage I
with P < 1 × 10−5 were carried forward for investigation in
Stage II. Effect estimates from Stage I and Stage II were then
meta-analyzed to obtain final estimates.
The associations between each genotyped/imputed genetic
marker (additive genotype model) and fibroid status were
assessed using multiple logistic regression while adjusting for up
to five top PCs with SNPTEST software (Marchini et al., 2007).
Interpretation of analyses from logistic regression models were
limited to genotyped and imputed markers which had a post-
imputation information score of ≥ 0.4, HWE P > 1 × 10−8,
and MAF ≥ 1%. Choice of MAF threshold was set so that
the expected count of minor alleles in cases, computed with
HWE assumptions, was ≥ 20 within each data set to mitigate
test statistic inflation due to sparse cells for lower frequency
variants (Supplementary Table 1). Associations across Stage
I, Stage II and Stage I + Stage II combined analyses were
performed using METAL software (Willer et al., 2010). Quantile-
quantile (QQ) plots for single SNP association analyses and
lambda estimates for individual studies in the discovery analysis
(Supplementary Figures 1a–k and Supplementary Table 1)
and their meta-analyses (Supplementary Figure 2) suggested
appropriate control of genomic inflation.
Genetic variants were considered to be statistically significant
and relevant for reporting if they met the following criteria: Stage
I and Stage II combined P < 5 × 10−8, Stage II P < 0.05 and
consistent directions of effect between Stage I and Stage II. At
its simplest form, when there was just one GWAS significant
SNP, a locus was defined as region centered around ± 500 kb of
the SNP. If more than one GWAS significant SNP was present
proximally in a given region, the locus for this region started
500 kb upstream from the first GWAS significant SNP and ending
500 kb downstream from the last GWAS significant SNP.
Conditional Analyses
We used two parallel approaches with the Genome-wide
Complex Traits Analysis (GCTA) software to perform
conditional analysis of common variants from the discovery
GWAS summary statistics: (i) locus-specific conditional
analysis, and (ii) genome-wide joint conditional analysis
(Yang et al., 2011,Wu et al., 2007). We used the BioVU EA
genetic data (N = 19,726) as the reference genotype-level data
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for LD approximation. Locus-specific conditional analyses were
performed for SNPs with MAF > 1% in all GWAS significant loci
in final meta-analysis. SNPs were considered to be conditionally
significant from these analyses if the SNP remained GWAS
significant after conditioning on the sentinel variant. Genome-
wide joint conditional analysis was also performed using
the full discovery GWAS summary statistics using the –cojo
method which performs iterative conditional and joint analysis
simultaneously with stepwise model selection. A p-value cut-off
of 5 × 10−8 was used as the selection threshold within GCTA,
and the collinearity threshold was set at the default R2 value
of 0.9, so that highly correlated SNPs are not selected in the
model. We then compared SNPs from both approaches and for
robustness, a secondary signal was only claimed if a given SNP
was validated from both approaches.
Post-GWAS Analyses
RegulomeDB
We further evaluated evidence for regulatory function in SNPs
identified in the genetic analyses by using RegulomeDB (Boyle
et al., 2012) and the Genotype-Tissue Expression (GTEx) portal
resource. RegulomeDB is a publicly available database which
annotates SNPs with known and predicted regulatory elements
using various sources of information including GEO, ENCODE
and other published literature. The web-based tool provides a
score for each SNP, where a lower score provides the greatest
evidence for regulatory functionality (Boyle et al., 2012).
S-PrediXcan
We evaluated the association between GPGE and uterine fibroid
risk using the S-PrediXcan software (Barbeira et al., 2018), a
meta-analysis extension of the PrediXcan method. PrediXcan is
a gene-based data aggregation and integration method which
incorporates information from gene expression and GWAS data.
Evidence of association with a phenotype is thus translated
from the SNP-level to gene expression level (Gamazon et al.,
2015). Briefly, PrediXcan first imputes gene-expression at an
individual level using prediction models trained on datasets
with data available on genetic variation and transcriptome
expression (The GTEx Consortium et al., 2015). It then regresses
the phenotype onto imputed transcriptome levels. S-PrediXcan
extends its application to allow inference of the direction
and magnitude of GPGE-phenotype associations with summary
statistics from GWAS, which is advantageous when SNP-
phenotype associations result from a meta-analysis setting and
also when individual level data are not available. S-PrediXcan
analyses were conducted in all 42 available GTEx tissues with
modes deposited at predictdb.org, excluding the prostate and the
testis. All Ps presented are two-sided.
eQTL-Based Summary Mendelian
Randomization (SMR)
We performed two-sample eQTL based SMR analyses using
GWAS significant SNPs from all 11 loci from the final meta-
analysis with the SMR software (Zhu et al., 2016). Briefly,
two-sample SMR is an instrumental variable approach to
investigating the relationship between an exposure and outcome,
in our case, gene expression in the uterine tissue and uterine
fibroids. This method is particularly advantageous when
exposure and outcome are not simultaneously collected. In
a two-sample SMR, the association between gene expression
and outcome is approximated taking a ratio of the association
between SNP and outcome (GWAS summary statistics)
and SNP and gene expression (eQTL of desired tissue
from GTEx), βSMR(Gene−Expression−fibroids) = βSNP−fibroids/
βSNP−eQTL−GTEx uterine tissue.
As input for the SMR analysis we provided summary statistics
for eQTLs in the GTEx uterine tissue, summary statistics for
GWAS significant SNPs at each locus from GWAS analysis,
and the 1000-Genomes reference population for LD estimation.
Analyses were performed separately at each locus allowing
inclusion of GWAS significant SNPs with R2 < 0.9, and
overlapping eQTL SNPs with P-values < 0.05. A cis-eQTL-gene
pair was not specified, rather, the software was allowed to evaluate
and report associations for cis-eQTL and gene pairs in a region
contained within ± 2000 KB of the index GWAS significant
SNP. Data are automatically harmonized to choose consistent
effect allele between summary GWAS and summary eQTL for
calculation of beta-estimates. The output allows inference of
association between gene expression at each locus and uterine
fibroids. When more than one eQTL-gene pair was identified
(GWAS significant SNP and eQTL P-value < 0.05) for a given
locus, these SMR results were sorted by P-value and reported.
DEPICT
Enrichment analyses in DEPICT (Pers et al., 2015) were
conducted using SNPs less than two P-value thresholds:
P < 5× 10−7, and P < 1× 10−5. DEPICT is based on predefined
phenotypic gene sets from multiple databases and Affymetrix
HGU133a2.0 expression microarray data from more than > 37k
subjects to build highly expressed gene sets for Medical Subject
Heading (MeSH) tissue and cell type annotations. Output
includes a P for enrichment and a yes/no indicator of whether
the FDR q-value is < 0.05. Tissue level and gene-set enrichment
features are considered.
RESULTS
We summarized participant characteristics in our study
populations in Table 1. Four of the nine studies in the imaging-
confirmed electronic medical record (EMR) case-control sets
from the eMERGE network were identified as AA, with the
remaining comprised of EA individuals. Participants from the
UKB were classified as African or European. Uterine fibroid
cases were younger than fibroid controls (P < 0.05) in eight
of the thirteen studies (Table 1). In agreement with previously
published studies, fibroid cases had higher mean BMI than
controls, with significant differences in six of the thirteen
studies (Table 1).
Single Variant Analyses
We conducted a two-stage analysis, discovery GWAS and
targeted replication, to investigate the association between single
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variants and fibroids (Figure 1). Genome-wide discovery meta-
analysis in 9,446 cases and 67,048 controls from 11 ancestry-
specific datasets from eMERGE and UKB (Stage I) identified 124
significant GWAS SNPs (P < 5 × 10−8), and 860 variants with
suggestive evidence (P < 1 × 10−5). Variants with significant
and suggestive evidence were tested for replication in UKB
(Stage II) African and European ancestry subsets (Stage II
N = 12,358 cases, 138,477 controls). Meta-analysis of Stage I
and Stage II effect estimates identified 326 variants from 11 loci
that surpassed GWAS significance, had a P < 0.05 in Stage
II replication and had consistent directions of effect between
discovery and replication meta-analysis sets (Figure 2, Table 2,
and Supplementary Figures 2–13).
Three of the 11 loci are novel. Among novel loci, sentinel
SNP rs4785384, on chromosome 16q12.1 near HEAT repeat
containing 3 (HEATR3) was most significantly associated with
fibroids (T allele Odds Ratio [OR] = 1.08; 95% confidence
interval [CI]: 1.05, 1.10; P = 1.45 × 10−9; heterogeneity p
[P-Het] = 0.38). The SNP had consistent directions of effect
in 12 out of 13 studies (Figure 3). Sentinel SNP rs78378222,
located in the 3′ untranslated region of the tumor protein p53
(TP53) gene, a known fibroid locus, was the most significant
association in the study (T allele OR = 0.54; 95% CI: 0.49, 0.60;
P = 3.24× 10−33; Het-P = 0.11). This variant is monomorphic in
the African reference populations and was an uncommon allele
only observed in datasets with European ancestry individuals
(minor allele frequency [MAF] = 1%).
Sentinel SNPs from other notable loci previously reported
in the literature include rs58415480 (P = 2.39 × 10−31), an
intron variant in the spectrin repeat containing nuclear envelope
protein 1 (SYNE1) gene, rs10835889 (P = 1.17 × 10−24) near the
Wilms Tumor 1 (WT1) gene, and rs3830738 (P = 2.73 × 10−13),
an intron variant in the trinucleotide repeat containing 6B
(TNRC6B) gene (Table 2). Directions of effect were consistent
across ancestry groups (African and European) for these
associations. SNP rs10917151 (P = 1.76 × 10−24) located
between cell division cycle 42 (CDC42) and the Wnt family
member 4 (WNT4) genes was positively associated with uterine
fibroids (A allele OR = 1.16; 95% CI: 1.13, 1.19). However,
stratifying analyses by race (African and European) showed effect
estimates for African and European ancestry were in opposite
directions (inverse, statistically non-significant association for
African (OR = 0.84; 95% CI: 0.62, 1.15) and positive association
for European ancestry (OR = 1.16; 95%: 1.13, 1.20); Het-P-
between-groups = 0.04; Figure 4).
Locus-specific conditional analyses of the discovery GWAS
summary statistics with GCTA did not identify additional
secondary signals at any of the 11 loci after conditioning on
the sentinel SNP at each locus. Genome-wide joint conditional
analysis of discovery GWAS data identified five variants that
remained significant before and after joint-conditional analyses
(Supplementary Table 2). These jointly modeled SNPs are
independent of each other, but not after conditioning on the
sentinel variant. Two of these five SNPs were the sentinel SNPs
at the locus (Supplementary Table 2).
Regulatory Annotations
We utilized the RegulomeDB resource to investigate the presence
of genetic variants with regulatory effects among GWAS
significant variants recognized by RegulomeDB (308 out of
326 SNPs) (Boyle et al., 2012). RegulomeDB scores aggregate
evidence for the presence of regulatory motifs for SNPs which
are ranked from 1a (most evidence) to 7 (no data). One hundred
thirty-eight variants were scored as regulatory (score of ≤ 5)
FIGURE 2 | Manhattan plot representing Stage I and II trans-ethnic meta-analyses. Black and gray dots represent Stage I SNPs only; red dots represent SNPs with
suggestive or greater evidence (P < 1 × 10-5) in Stage I, but not replicated in Stage II (P > 0.05). Golden dots represent SNPs with P < 5 × 10-8 after meta-analysis
of Stage I and Stage II + Stage II P-value < 0.05 + consistent directions of effect between Stage I and Stage II
Frontiers in Genetics | www.frontiersin.org 7 June 2019 | Volume 10 | Article 511





~ . i 
g; :.! ' ,s 
I 
Chromosome 
fgene-10-00511 June 11, 2019 Time: 18:1 # 8
Edwards et al. Trans-Ethnic Fibroids GWAS
TABLE 2 | Sentinel SNPs from trans-ethnic genome-wide meta-analysis of 13 African and European ancestry studies.
SNP CHR BP EFF/ OTH Nearby Genes Freq OR (95% CI) P Direction HetP
rs17361789# 1 172,122,601 T/G DNM3∗ 0.68 0.94 (0.92, 0.96) 4.67 × 10−8 +—??–+?–+ 0.29
rs4785384# 16 50,147,993 T/C HEATR3 0.73 1.08 (1.05, 1.10) 1.45 × 10−9 ++++−++++++++ 0.38
rs6094982# 20 46,761,257 A/T LOC105372640 0.04 2.09 (1.61, 2.70) 2.55 × 10−8 +??+???????++ 0.05
rs10917151 1 22,422,721 A/G CDC42, WNT4 0.16 1.16 (1.13, 1.19) 1.76 × 10−24 −++−??+++?++− 0.41
rs58415480 6 152,562,271 C/G SYNE1∗ 0.84 0.84 (0.82, 0.87) 2.39 × 10−31 ——–+—− 0.73
rs1812264 9 805,427 T/G LOC105375949∗ 0.61 0.91 (0.89, 0.93) 1.31 × 10−18 +++−+–++–− 0.15
rs7907606 10 105,680,632 T/G OBFC1 0.81 0.89 (0.87, 0.92) 2.49 × 10−16 —-+–+–− 0.81
rs7124615 11 186,604 T/C SCGB1C1, BET1L 0.14 0.86 (0.83, 0.89) 1.28 × 10−20 +–+++–+–− 0.12
rs10835889 11 32,370,380 A/G WT1 0.18 1.16 (1.13, 1.19) 1.17 × 10−24 +++++++++++++ 0.96
rs78378222 17 7,571,752 T/G TP53∗∗ 0.99 0.54 (0.49, 0.60) 3.24 × 10−33 ?−+???????–? 0.11
rs3830738 22 40,711,227 A/AT TNRC6B∗ 0.79 0.91 (0.89, 0.93) 2.73 × 10−13 −+–+—++— 0.21
SNP, Single Nucleotide Polymorphism; CHR, Chromosome; BP, SNP Base Position in dbSNP build 37; EFF, Effect allele; OTH, other allele; Freq, frequency for effect allele
averaged across all relevant studies; OR, odds ratio; 95% CI, 95% Confidence Interval; Het-P, P for test assessing heterogeneity across studies. Order of studies for the
direction column: BioVU AA, BioVU EA, BioVU Stage II EA, BioME AA, Mount Sinai AA, eMERGE I AA, eMERGE I EA, Northwestern EA, Mayo EA, UKB AA (Stage I), UKB
EA (Stage I); UKB EA (Stage II), UKB AA (Stage II) #Novel loci; ∗ = Intron variant; ∗∗ = 5′/3′ UTR variant.
FIGURE 3 | Forest plot showing odds ratio estimates from individual studies and meta-analysis for SNP rs4785384. Meta-analyses were conducted using
inverse-variance weighted fixed-effects meta-analysis to present odds ratios and 95% confidence intervals. Study column represents participating study names by
strata of race. FREQ represents allele frequency for the effect allele coded in the plot.
(Supplementary Table 3). One SNP in chromosome 16q12.1,
rs6500288 (score: 1f), showed the greatest evidence for being in
a regulatory region, suggesting the SNP is an eQTL for a nearby
gene. The GTEx Project portal showed this SNP is a significant
eQTL for the HEATR3 gene in the lung, tibial nerve, thyroid, tibial
artery, esophagus muscularis, and several other tissues (Largest
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rs4785384 
Effect allele/Other allele = T JC 
Odds % 
Study Frequency Ratio (95% Cl) Weight 
Mount Sinai AA 0.24 0.84 (0.48, 1.46) 0.18 
BioVUAA 0.27 1.02 (0 .85, 1.21) 1.88 
eMERGEIEA 0.74 1.03 (0 .87, 1.20) 2.24 
UKBIIEA 0.75 • 1.07 (1 .03, 1 .10) 60 .70 I UKBIEA 0.75 ♦ 1.07 (1 .02, 1 .12) 26.89 
eMERGEIAA 0.28 1.11 (0 .62, 2.00) 0.17 
BioME AA 0.27 1.18 (0 .92, 1.51) 0.92 
Mayo EA 0.79 1.22 (0.87, 1.71) 0.49 
UKB II AA 0.22 1.22 (0.93, 1.61) 0.77 
BioVU EA 0.75 • 1 .23 (1 .08, 1 .41) 3.26 
BioVU EA II 0.74 1.24 (0.99, 1.55) 1.11 
NWEA 0.76 1.27 (0.94, 1.72) 0.61 
UKBIAA 0.25 1.31 (1 .00, 1.70) 0.79 
Overall (I-squared = 6.6%, p = 0.380) ~ 1.08 (1.05, 1.10) 100.00 
.48 2.08 
Decreased odds Increased odds 
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FIGURE 4 | Forest plot showing odds ratio estimates from individual studies and meta-analysis for SNP rs10917151 by continental ancestry strata – African and
European origin. Meta-analyses were conducted using inverse-variance weighted fixed-effects meta-analysis to present odds ratios and 95% confidence intervals for
studies within each continental ancestry strata. Study column represents participating study names by strata of race. FREQ represents allele frequency for the effect
allele coded in the plot. Heterogeneity between groups P compares odds ratios between the two strata.
P = 1 × 10−6 in the liver; and Smallest P = 1.9 × 10−50 in the
lung). Six SNPs on chromosome 11, four SNPs on chromosome
1, two SNPs on chromosome 2, two SNPs on chromosome 9 and
one SNP on chromosome 17 also were scored as regulatory with
RegulomeDB scores of 2a and 2b.
Transcriptome-Wide Association
Analysis
We used S-PrediXcan along with 42 tissues from the GTEx
project (excluding male-specific tissues) to identify associations
between GPGE and uterine fibroid risk (Figure 5 and Table 3).
Increasing GPGE of LUZP1 in the vagina tissue was positively
associated with uterine fibroids (Z-score = 5.47; P = 4.6 × 10−8;
Figure 6 and Table 3). The gene lies in the same chromosome
1p36.12 region as the CDC42 and WNT4 genes. There was
suggestive evidence for predicted expression of CDC42 in the
tibial artery and fibroids (Z-score = 4.48; P = 7.4 × 10−6).
GPGE analyses also identify OBFC1 on chromosome 10. OBFC1
expression in the esophagus mucosa was inversely associated
with uterine fibroids (Z-score = −5.35; P = 8.7 × 10−8;
Figure 7 and Table 3). Additionally, increased GPGE of NUDT13
across multiple tissues (subcutaneous adipose transformed
lymphoblasts, esophagus muscularis, and breast mammary
tissue) was positively associated with fibroid risk (Table 3).
Consistent with the GWAS nearest-gene approach, RegulomeDB
prediction and GTEx eQTL confirmation, increasing GPGE of
HEATR3 in skeletal muscle was positively associated with fibroids
(P = 5.8 × 10−6). Although we did not find a significant
association between GPGE of WT1 and fibroids, its RNA
expression is highest in the uterus tissue (N samples = 111),
followed by the fallopian tube (N samples = 7), and ovary (N
samples = 133) (Figure 7). The GTEx portal does not identify
strong eQTLs for the WT1 gene.
Summary Mendelian Randomization
We identified associations between gene expression in the
uterine tissue and fibroids in eight of the eleven GWAS
significant loci investigated with SMR (Supplementary
Table 4). HEATR3, located in 16q12.1 was the most significant
association in SMR analyses, and its gene expression was
positively associated with uterine fibroids (βSMR = 0.165;
P-value 1.1 × 10−5). SMR for this gene was evaluated using
rs6500288, a SNP that is in perfect LD (R2 = 1) with the index
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rs10917151 
Effect allele/Other allele = A/G 
Study FREQ 
Afr 
BioVU AA 0.03 
BioME AA 0.04 
UKB II AA O.D1 
Subtotal (I-squared = 0.0%, p = 0.709) 
Eur 
Mayo EA 0.17 
eMERGEIEA 0 .16 
UKB II EA 0.16 
BioVU EA 0.16 
UKB I EA 0.16 
BioVU EA II 0 .16 
NWEA 0.16 
Subtotal (I-squared = 0.0%, p = 0.602) 
Heterogeneity between groups: p = 0.043 











Ratio (95% Cl) Weight 
0.75 (0.50, 1.14) 0.48 
0.98 (0.58, 1.65) 0.29 
0.98 (0 .35, 2.80) 0.07 
0.84 (0.62 , 1.15) 0.84 
1.05 (0.74 , 1.51) 0.64 
1.06 (0.88, 1.29) 2.27 
1.15 (1.11, 1.19) 63.38 
1.17 (1.00 , 1.37) 3.22 
1 .20 (1 .14, 1 .27) 27.79 
1.30 (1.00 , 1.69) 1.19 
1.31 (0.92, 1.86) 0.66 
1.16 (1.13, 1.20) 99.16 
1.16 (1.13 , 1.19) 100.00 
2.88 
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FIGURE 5 | Genetically predicted gene expression in 42 GTEx tissues and uterine fibroids with S-PrediXcan. Top panel represents gene-level –log10 P-values from
S-PrediXcan; bottom panel dots represent log10 P-values from GWAS evaluating SNPs and uterine fibroids.
SNP rs4785384. WT1-AS was the most significant gene in the
11p13 locus and was positively associated with uterine fibroids
(βSMR = 0.22; P-value = 2.2× 10−3). The 1p36.12 locus harboring
WNT4 showed evidence for several candidate genes including
ECE1 (βSMR = 0.33; P-value = 4.9 × 10−3). WNT4 was positively
associated with uterine fibroids, however, the statistical evidence
was marginal (βSMR = 0.57; P-value = 5.57× 10−2).
Tissue Enrichment Analyses With
DEPICT
We further applied the DEPICT method to the top results
from our GWAS analyses (P < 5 × 10−7) to evaluate
evidence of tissue or gene-pathway level enrichment.
Although results were not statistically significant after
considering multiple comparisons (FDR < 5%), the top
TABLE 3 | Summary of genetically predicted gene expression and fibroids risk in 42 GTEx tissues.
Gene Region Z-Score P Var-G R2 Q-value SNPs Used N SNPs in Model N Tissue
LUZP1 1p36.12 5.47 4.6 × 10−8 0.068 0.102 1.4 × 10−2 13 13 Vagina
OBFC1 10q24.33 −5.35 8.7 × 10−8 0.062 0.050 3.9 × 10−4 33 38 Esophagus Mucosa
C1orf234 1p36.12 −5.28 1.3 × 10−7 0.009 0.010 4.0 × 10−2 5 5 Tibial Nerve
NUDT13 10q22.2 4.65 3.3 × 10−6 0.300 0.292 3.0 × 10−23 100 102 Subcutaneous Adipose
MAPKBP1 15q15.1 −4.64 3.5 × 10−6 0.020 0.038 4.8 × 10−4 17 19 Subcutaneous Adipose
DNAJC9 10q22.2 4.63 3.7 × 10−6 0.052 0.059 2.8 × 10−3 55 56 Atrial Appendage
NUDT13 10q22.2 4.57 4.9 × 10−6 0.271 0.299 2.7 × 10−9 51 55 Transformed Lymphoblasts
NUDT13 10q22.2 4.56 5.2 × 10−6 0.317 0.379 3.2 × 10−23 114 118 Esophagus Muscularis
HEATR3 16q12.1 4.53 5.8 × 10−6 0.128 0.169 1.1 × 10−15 48 49 Skeletal Muscle
CDC42 1p36.12 4.48 7.4 × 10−6 0.012 0.008 4.4 × 10−2 22 22 Tibial Artery
FAM149B1 10q22.2 −4.48 7.4 × 10−6 0.014 0.038 1.2 × 10−2 33 36 Stomach
PLA2G4B 15q15.1 4.48 7.6 × 10−6 0.044 0.065 1.3 × 10−3 12 12 Stomach
JMJD7 15q15.1 4.47 7.7 × 10−6 0.196 0.362 3.0 × 10−30 26 28 Sun Exposed Skin Lower Leg
NUDT13 10q22.2 4.47 7.9 × 10−6 0.181 0.303 7.2 × 10−15 112 113 Breast Mammary Tissue
NUDT13 10q22.2 4.43 9.2 × 10−6 0.343 0.368 2.2 × 10−26 75 77 Tibial Nerve
PLA2G4B 15q15.1 4.43 9.6 × 10−6 0.022 0.082 1.6 × 10−4 9 10 Visceral Omentum Adipose
Var-G, variance of the gene’s predicted expression, calculated as W’ × G × W (where W is the vector of SNP weights in a gene’s model, W’ is its transpose, and G is
the covariance matrix); R2, Performance prediction correlation; Q-value, FDR derived Q-value. Only predicted gene models with FDR Q-values < 0.05 are considered
for genetically predicted gene expression association; SNPs used N, number of SNPs included in the prediction model for that gene available in the summary statistics;
SNPs in Model N, number of SNPs used to construct the prediction model for the gene in the tissue of interest using the GTEx data; Bonferroni Significance (Sum of
N-genes across all tissues tested): 0.05/194549 = 2.57 × 10−7;Suggestive Significance (N-Unique genes tested across all tissues tested): 0.05/17433 = 2.87 × 10−6.
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FIGURE 6 | Regional S-PrediXcan and SNP association plot for WNT4, CDC42, and LUZP1 loci. (Top) Represents gene-level –log10 P-values from S-PrediXcan;
(bottom) dots represent log10 P-values from GWAS evaluating SNPs and uterine fibroids.
FIGURE 7 | Regional S-PrediXcan and SNP association plot for OBFC1 locus. (Top) Represents gene-level –log10 P-values from S-PrediXcan; (bottom) dots
represent log10 P-values from GWAS evaluating SNPs and uterine fibroids.
enriched tissue from these analyses was myometrium as
the first-level MeSH term and the urogenital system as
corresponding top second-level MeSH term (P = 0.056)
(Supplementary Table 5). The urogenital system accounted
for eight out of the top 20 MeSH groupings based GWAS
results from this study. Similar results were obtained when the
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DEPICT method was applied with SNPs with P < 1 × 10−5
(Supplementary Table 6).
DISCUSSION
Several lines of evidence support that there is a genetic
component of uterine fibroid risk. However, because of study
design and ascertainment challenges, there have been few large
GWAS for fibroids. Only one study, previously published by our
research group, has included AAs with fibroid cases and controls
verified by imaging, and only one recent study has meta-analyzed
multiple ancestral populations with relatively small number of
women with African ancestry. Here we investigated common
genetic variants and risk for fibroids in AA and EA women with
image-verified classification of case-control status from EMRs in
the US and in women of European and African ancestry with
diagnosis-verified fibroid case status from the UKB. We report
associations for 11 genome-wide significant loci, of which eight
have been previously reported and three are novel. We add
evidence to relevant gene targets in relation to uterine fibroid
risk by integrating GWAS data with GPGE weights across 42
tissues, and by performing locus-specific eQTL SMR analyses
with the uterine tissue.
Sentinel SNP rs4785384, the most significant novel variant,
located near the HEATR3 gene had consistent directions of
association in 12 out of 13 race- and site- specific assessments in
this study. Increasing GPGE of HEATR3 in skeletal muscle was
positively associated with fibroids and SMR analyses suggested
increasing HEATR3 expression in the uterine tissue is positively
associated with uterine fibroids. The gene product of HEATR3
plays a role in the transport and assembly of the ribosomal 5S
ribonucleoprotein particle. In recent findings, genetic variants
related to HEATR3 have been associated with increased risk of
glioblastoma (Melin et al., 2017a) and esophageal cancer (Jia et al.,
2015). The effect allele is common in all 1000G populations, and
provides an example of a genetic association for fibroids that is
shared across ethnicities.
The second novel locus, DNM3 (sentinel-SNP: rs17361789),
was proposed as a tumor suppressor gene for hepatocellular
carcinoma (Inokawa et al., 2013) and is suspected to control
carcinoma growth by activating p53 (Gu et al., 2017, p. 3), which
is the gene product of the most significant locus detected in
our study Tumor Protein 53 (TP53) (sentinel-SNP: rs78378222).
TP53, a tumor suppressor gene, is one the most frequently
mutated genes in many human cancers (Kastenhuber and Lowe,
2017) and has also been associated with fibroids (Rafnar et al.,
2018). The sentinel variant for TP53 is polymorphic in European
derived reference populations and monomorphic in African
populations in the 1000 genomes reference providing further
evidence for presence of race-specific risk loci in relation to
uterine fibroids.
Our study also provides evidence of association for several
previously reported genetic loci including TNRC6B, BET1L and
OBFC1. First shown by Cha et al. (2011a) in a Japanese population
in 2011, variants from these genes have since been associated with
uterine fibroid risk in candidate gene studies conducted in Saudi
women (Bondagji et al., 2017), white women (Edwards et al.,
2013b), and now in this trans-ethnic analysis of white and black
women from the United States and the United Kingdom. Another
study from our group reported associations between variations in
the TNRC6B gene and fibroid volume (Edwards et al., 2013a).
Several studies have reported associations between variants
near OBFC1 and fibroids (Cha et al., 2011b; Rafnar et al., 2018;
Välimäki et al., 2018). OBFC1 has been suggested to play a role
in maintaining telomere length and SNPs in this locus have
been associated with many cancers including melanoma (Law
et al., 2015; Ransohoff et al., 2017), glioma and non-glioblastoma
glioma (Melin et al., 2017b), thyroid (Gudmundsson et al., 2017),
basal cell carcinoma (Chahal et al., 2016), renal cell carcinoma
(Scelo et al., 2017), ovarian cancer (Phelan et al., 2017), and lung
adenocarcinoma (McKay et al., 2017). Our findings are the first
to observe that increased GPGE of OBFC1 is associated with
reduced risk of uterine fibroids, although Phelan et al noted
that the sentinel SNP in OBFC1 for ovarian cancer was likely
regulatory (Phelan et al., 2017).
The WT1 gene lies within 100 kb of the index SNP
(rs11828433) on chromosome 11p13. Index SNP rs11828433,
along with other genome-wide significant variants in this
region showed consistent directions of association across studies
and is a common variant in European and African ancestral
populations. WT1 encodes a transcription factor and plays
a crucial role in the development of the urogenital system.
Among all tissues in GTEx, WT1 is most expressed in the
uterine tissue, followed by other reproductive tissues (Figure 5).
Haploinsufficiency of WT1 is associated with Wilms tumor,
while dysregulated WT1 expression is associated with tumors
including leukemia, testicular germ cell tumors and uterine
leiomyosarcoma (Coosemans et al., 2011; Boublikova et al., 2016;
Cebinelli et al., 2016; Naitoh et al., 2016). Two other studies
have reported marginal associations between variants rs12789861
(Shmygelska et al., 2013), and rs1223079 (Aissani et al., 2015) at
this locus and fibroids (Supplementary Figure 14); and the most
recent study showed genome-wide significant associations at this
locus (Rafnar et al., 2018).
The chromosome 1p36.12 region containing the CDC42 and
WNT4 genes, was statistically the second most significant region
from GWAS analysis. CDC42 and WNT4 were the closest genes
to the top SNPs in this locus, however, incorporating tissue
expression data suggested Leucine Zipper Protein 1 (LUZP1)
expression in the vagina, rather than WNT4 or CDC42, as
the gene most associated with fibroid risk. LUZP1 has been
implicated as a negative transcription regulator; however, the
mechanism by which transcript abundance of this gene would
affect uterine fibroid risk is unclear. Increased expression of
WNT4 has been found in studies of fibroid tumors that carry
somatic MED12 mutations (Markowski et al., 2012). However,
it is not clear from somatic studies if the increase in WNT4
expression is a consequence of uterine fibroid growth, or a cause.
In contrast with the somatic studies that support a positive
relationship between WNT4 expression and the fibroid state,
increasing GPGE of WNT4 in thyroid tissue is non-significantly
inversely associated with uterine fibroid risk (P = 2.2 × 10−5).
A deeper evaluation of the index SNP rs10917151 in the GTEx
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database showed this SNP is not a strong eQTL for WNT4 and
the direction of association varies by tissue type, with a non-
significant yet positive association in the uterus (Supplementary
Figure 14). Our SMR analyses in region suggested a positive
association between WNT4 expression in the uterine tissue and
fibroids risk, as shown in the literature. However, our results also
highlight the possibility that other genes in this locus may be
associated with uterine fibroids.
This study also reports evidence of association with ancestry-
specific alleles that may influence fibroid risk and health
disparities between populations. The top variant in the
WNT4/CDC42 had opposite directions of effect in African
and European ancestry women, and associated variants in the
TP53 locus were only polymorphic in European women. We
have previously reported evidence for differential burdens of
risk-increasing alleles for fibroproliferative traits across global
populations that are consistent with prevalence disparities
(Hellwege et al., 2017b). This finding was recently extended to
evaluate only fibroid risk variants across populations, with an
increased mean burden of risk alleles in black fibroid cases and
controls from UKB compared to other racial/ethnic groups, with
a similar result using frequencies from the gnomAD browser
(Välimäki et al., 2018).
This study is the largest multi-stage trans-ethnic genome-
wide investigation of uterine fibroid risk. Utilizing validated
algorithms for fibroid case-control identification in multiple
EMR-linked biobanks in the United States, and diagnosis-
confirmed fibroid cases with appropriate female controls in the
UKB, this study verifies several previously reported loci, reports
variants at novel loci, and extends inferences using summary
Mendelian randomization and predicted gene expression in
relation to uterine fibroids. The study also provides evidence for
the presence of shared and ancestry specific genetic loci which
may influence fibroid risk and disparities. Further fine-mapping,
and characterization of mechanisms involved will help elucidate
the role of variants and genes reported in this study.
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